Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

NPF Study Finds that Regular Exercise Can Slow Decline in Quality of Life

Data from the Parkinson’s Outcomes Project Presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders

MIAMI, June 17, 2015—Data released today from the National Parkinson Foundation’s (NPF) Parkinson’s Outcomes Project shows that people with Parkinson’s disease (PD) who start exercising earlier experience a significant slower decline in quality of life than those who start later. The study is being presented today by NPF researchers at the 19th International Congress of Parkinson’s Disease and Movement Disorders in San Diego, CA. 

“This study makes it clear that everyone with Parkinson’s disease should be exercising. Patients suffer when they delay starting their exercise, and it doesn’t seem to matter what they do, they benefit from just getting up and moving,” said Michael S. Okun, MD, NPF’s National Medical Director. 

Researchers looked at data on nearly 3,000 patients receiving care for three years at NPF Centers of Excellence participating in the Parkinson’s Outcomes Project—the largest clinical study of Parkinson’s ever conducted. Over 1,300 of the study participants reported little regular exercise at the beginning of the study. Five hundred of those individuals began exercising greater than 2.5 hours per week within the next two years. The researchers compared participants who exercised regularly for the entire two years, to people who didn’t exercise at the beginning of the study, but then started to exercise regularly.

In this study, they didn’t separate what types of exercise were done, just the total exercise reported. Quality of life scores were compared using the Parkinson’s Disease Questionnaire (PDQ-39). The PDQ-39 is a self-reported questionnaire that measures the impact of PD on daily life through multiple factors, including mood, movement and social interaction.  Over the two-year study period, the PDQ-39 scores worsened 1.4 points in the early starters and 3.2 points in the late starters.

“This analysis is interesting because it is structured as a ‘delayed start’ trial, comparing people who start early versus those who start late.  This design is the standard approach to show an intervention slows the disease: if it just improved symptoms, people who start late would get the same benefit as those who start early,” explained Peter Schmidt, PhD, NPF’s Senior Vice President and Chief Mission Officer and an author of the study.  “We found that people who start exercise early get more benefit than those who start late.”

Lead study author Miriam Rafferty, PT, DPT, whose doctoral research at the University of Illinois at Chicago focuses on exercise and Parkinson’s, noted that this difference of almost two points on the PDQ-39 could be enough to make everyday activities feel harder.

“This is great news that people can have a positive impact on the course of their own disease,” said Joyce Oberdorf, NPF’s President and CEO. “It is tremendously empowering.” 

NPF's Parkinson's Outcomes Project is the largest clinical study of Parkinson's disease ever conducted with more than 8,000 patients with PD who receive care at 20 NPF Centers of Excellence in four countries. NPF issued care recommendations in 2012 around the issue of depression A mood disorder whose symptoms can include a persistent sad or empty mood, feelings of hopelessness or pessimism, irritability and loss of interest or pleasure in previously enjoyable activities. in PD after finding that it was undiagnosed in the patients tracked through the study.  The goal of the Parkinson's Outcomes Project is to continue to identify best care practices for Parkinson's that could help get better care to more people affected by the disease.   For more information about NPF's research initiatives, visit www.parkinson.org/research.

About Parkinson's Disease (PD)
Affecting an estimated one million Americans and four to six million worldwide, PD is the second most common neurodegenerative disease after Alzheimer's and is the 14th leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression) as well as non-motor symptoms (e.g., depression and anxiety A feeling of nervousness, worried thoughts and physical distress.). There is no cure for PD and 60,000 new cases are diagnosed each year in the United States alone.

Wednesday, June 17, 2015
In Memory of Robert Traurig
Wednesday, July 18, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member Robert (Bob) Traurig. From 2004 to 2015, he was a member of the Foundation’s board of directors. Bob is survived by his wife Jacqueline, his daughters Madeline Sackel and Wendy Traurig.

New Study Shows 1.2 Million People in the United States Estimated to be Living with Parkinson’s Disease by 2030
Tuesday, July 10, 2018

Parkinson’s Foundation Reveals Most Comprehensive Estimate of
Parkinson’s Prevalence in North America since the 1970’s

Parkinson’s Foundation Elects Howard D. Morgan Chairman of the Board
Tuesday, June 26, 2018

MIAMI & NEW YORK — June 26, 2018 — The Parkinson’s Foundation today announced the election of Howard D. Morgan as chairman of its board of directors. Mr. Morgan, who previously served as the Vice Chair of the nonprofit organization’s board, is a Partner and the Senior Managing Director of Argand Partners in New York.

Parkinson’s Foundation Announces Five New Members of its People with Parkinson’s Advisory Council
Wednesday, June 13, 2018

NEW YORK & MIAMI — June 13, 2018 — The Parkinson’s Foundation today announced five new members of its People with Parkinson’s Advisory Council.

The Parkinson’s Foundation 2018 Gala in New York City Tuesday, May 8, 2018
Monday, May 14, 2018

The Parkinson’s Foundation 2018 Gala was held at Cipriani 25 Broadway in New York City on Tuesday, May 8, 2018.

Parkinson’s Foundation Adds Alison Herman to its Board of Directors
Tuesday, May 8, 2018

MIAMI – May 9, 2018 – The Parkinson’s Foundation today announced the election of Alison Herman to its board of directors. Herman is senior counsel at Southern Glazer’s Wine & Spirits, a company which has generously supported Parkinson’s Foundation fundraisers.

Statement on Nuplazid Drug
Tuesday, April 10, 2018

On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and psychosis in Parkinson’s disease. The article investigates FDA data showing the number of reported deaths with people taking Nuplazid. Nuplazid was approved by the FDA in 2016 and is manufactured by Acadia Pharmaceuticals.

Parkinson’s Foundation Adds John D. Thomopoulos to its Board of Directors
Monday, March 19, 2018

MIAMI & NEW YORK – March 19, 2018 – The Parkinson’s Foundation today announced the election of John D. Thomopoulos to its board of directors. Thomopoulos is a partner at Ernst & Young.

In Memory of Edythe Kay Marsa
Monday, March 12, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member, Edythe (Edy) Kay Marsa. From 1993 to 2014, she was a member of the Foundation’s board of directors and served on several committees. Edy is survived by her husband William Marsa, who founded the Herbert Kay Parkinson Chapter in honor of her first husband who passed away due to complications from Parkinson’s disease.

Parkinson’s Foundation Announces New Genetic Initiative Connecting Parkinson’s Genetic Data with Clinical Care
Tuesday, March 6, 2018

MIAMI & NEW YORK—March 6, 2018—The Parkinson’s Foundation today announced a new initiative offering genetic testing and counseling to Parkinson’s patients within its Center of Excellence network.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.